Pamonag Michael Zambarrano, Seery Alexis Marie, Omari Ahmad Issa Al, Alnouri Ghiath, Sataloff Robert T
Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
Jordan University of Science and Technology, Irbid, Jordan.
J Voice. 2023 Aug 22. doi: 10.1016/j.jvoice.2023.07.017.
This is a systematic review aimed to explore Cidofovir administration protocols, recurrence rates, and long-term effectiveness for severe cases of recurrent respiratory papillomatosis (RRP). The primary goal was to identify current practices, determine the preferred protocol, and assess the adjuvant therapy's ability to prevent long-term papilloma recurrence in juvenile and adult-onset disease.
The following databases were searched: Pubmed, Google Scholar (pages 1-10), EMBASE, Scopus, ISI (clarivate), Cochrane Library, and Journal Storage from 1996 to June 2022. Articles that reported the use of intralesional Cidofovir in RRP and reported remission/recurrence rates with follow-up were included in the review. The systematic review was registered through PROSPERO and contains the detailed protocol for the conduction of the review.
A total of 389 records were identified, 126 titles and abstracts screened, 45 studies fully read, and 30 studies met the inclusion criteria. Two hundred and fourteen adult-onset RRP (AORRP) and 126 juvenile-onset RRP (JORRP) cases were treated with Cidofovir across the included studies. There was no universal protocol for administering Cidofovir, with variations in concentration, treatment period, number and interval of injections, and follow-up duration. Most lesions showed human papilloma virus types 6 and 11. Recurrence rates varied, and other outcomes reported included remission rates, lesion reduction, surgical intervals, and side effects. Some studies demonstrated significant improvements in disease severity and extended intervals between recurrences after Cidofovir administration.
The analysis of 30 studies reveals the need for greater consistency in reporting treatment parameters and outcomes. The use of recurrence-free period as an outcome measure and the potential benefits of a concentration of 7.5 mg/mL are identified. Additionally, the importance of viral typing within papilloma lesions is emphasized. To further enhance understanding and establish optimal protocols, future research should focus on uniform reporting, including severity, dosage, interval, treatment duration, functional outcome, and related procedures.
PROSPERO CRD42022299549.
本系统评价旨在探讨西多福韦的给药方案、复发率以及对复发性呼吸道乳头状瘤病(RRP)重症病例的长期疗效。主要目标是确定当前的治疗方法,确定首选方案,并评估辅助治疗预防青少年和成人发病型疾病中长期乳头状瘤复发的能力。
检索了以下数据库:PubMed、谷歌学术(第1 - 10页)、EMBASE、Scopus、ISI(科睿唯安)、考克兰图书馆以及1996年至2022年6月的期刊存储库。纳入本评价的文章需报告在RRP中使用病灶内注射西多福韦的情况,并报告随访时的缓解/复发率。该系统评价已在国际前瞻性系统评价注册库(PROSPERO)注册,并包含进行该评价的详细方案。
共识别出389条记录,筛选了126篇标题和摘要,详细阅读了45项研究,30项研究符合纳入标准。在纳入的研究中,共214例成人发病型RRP(AORRP)和126例青少年发病型RRP(JORRP)病例接受了西多福韦治疗。西多福韦的给药没有通用方案,在浓度、治疗周期、注射次数和间隔以及随访时间方面存在差异。大多数病变显示人乳头瘤病毒6型和11型。复发率各不相同,报告的其他结果包括缓解率、病变缩小、手术间隔和副作用。一些研究表明,使用西多福韦后疾病严重程度有显著改善,复发间隔延长。
对30项研究的分析表明,在报告治疗参数和结果方面需要更大的一致性。确定了将无复发期作为结局指标的用途以及7.5mg/mL浓度的潜在益处。此外,强调了乳头状瘤病灶内病毒分型的重要性。为了进一步增进理解并建立最佳方案,未来的研究应侧重于统一报告,包括严重程度、剂量、间隔、治疗持续时间、功能结局和相关程序。
国际前瞻性系统评价注册库(PROSPERO)CRD42022299549。